REACH2 is the first Phase III study in steroid-refractory acute graft-versus-host-disease (GvHD) to have met its primary endpoint
Imagine a Fitbit that measures much more than steps, heart rate, and calories burned. It continually tracks all […]
Three Boston University computer scientists and engineers are working on a smartphone app that could let people know […]
Covid-19Care home residents and staff are promised testsThe pledge to boost covid-19 testing for staff in UK care […]
Updated Date: Wed, 15 Apr 2020 00:00:00 EDT
Updated Date: Wed, 15 Apr 2020 00:00:00 EDT
Updated Date: Wed, 15 Apr 2020 00:00:00 EDT
Updated Date: Wed, 15 Apr 2020 00:00:00 EDT
Updated Date: Wed, 15 Apr 2020 00:00:00 EDT
